The objective of this study was to design and prepare a new contrast agent of magnetic resonance (MR) imaging for the evaluation of therapeutic angiogenesis. Diethylenetriaminepentaacetic acid (DTPA) residue of a chelator was chemically introduced to dextran with a molecular weight of 74,000 (dextran-DTPA). Cyclic peptide containing an arginine-glycine-aspartic acid (RGD) sequence (cyclic RGD) with an inherent affinity for the αvβ3 integrin was then introduced to dextran-DTPA (Cyclic RGD-dextran-DTPA). Gd3+ was added to cyclic RGD-dextran-DTPA to prepare a dextran-based MR contrast agent (Cyclic RGD-dextran-DTPA-Gd). Cyclic RGD-dextran-DTPA-Gd had affinity for cells expressing the αvβ3 integrin and showed a higher longitudinal relaxivity compared with DTPA-Gd of an MR contrast agent clinically used. Right femoral, external iliac, and deep femoral and circumflex arteries and veins were surgically ligated to prepare a mouse model of hindlimb ischemia. A laser Doppler analysis and histological evaluation confirmed that hindlimb ischemia healed naturally and was accompanied by angiogenesis, while αvβ3 integrin was expressed in the ischemic-angiogenic region without any treatment. Mice at 7 days after vascular ligation were used as an angiogenesis model. When intravenously injected into mice with hindlimb ischemia, cyclic RGD-dextran-DTPA accumulated in the ischemic-angiogenic region and showed the MR ability to detect the ischemic-angiogenic region. It is concluded that cyclic RGD-dextran-DTPA-Gd is a promising material for evaluation of therapeutic angiogenesis.
YamamotoM., TakahashiY., TabataY.Controlled release by biodegradable hydrogels enhances the ectopic bone formation of bone morphogenetic protein. Biomaterials, 24:4375. 2003.
3.
ItohM., HiraokaY., KataokaK., HuhN.H., TabataY., OkochiH.Novel collagen sponge reinforced with polyglycolic acid fiber produces robust, normal hair in murine hair reconstitution model. Tissue Eng, 10:818. 2004.
4.
KojimaK., IgnotzR.A., KushibikiT., TinsleyK.W., TabataY., VacantiC.A.Tissue-engineered trachea from sheep marrow stromal cells with transforming growth factor beta2 released from biodegradable microspheres in a nude rat recipient. J Thorac Cardiovasc Surg, 128:147. 2004.
5.
BajadaS., MazakovaI., RichardsonJ.B., AshammakhiN.Updates on stem cells and their applications in regenerative medicine. J Tissue Eng Regen Med, 2:169. 2008.
6.
MaruiA., TabataY., KojimaS., YamamotoM., TambaraK., NishinaT., SajiY., InuiK., HashidaT., YokoyamaS.et al.A novel approach to therapeutic angiogenesis for patients with critical limb ischemia by sustained release of basic fibroblast growth factor using biodegradable gelatin hydrogel: an initial report of the phase I-IIa study. Circ J, 71:1181. 2007.
7.
Lysiak-DrwalK., DominiakM., SolskiL., ZywickaB., PielkaS., KonopkaT., GerberH.Early histological evaluation of bone defect healing with and without guided bone regeneration techniques: experimental animal studies. Postepy Hig Med Dosw (Online), 62:282. 2008.
8.
DagliogluE., DikeM.S., KilincK., ErdoganD., TakeG., ErgungorF., OkayO., BiyikliZ.Neuroprotective effect of melatonin on experimental peripheral nerve injury: an electron microscopic and biochemical study. Cent Eur Neurosurg, 70:109. 2009.
9.
FuX.B., SunT.Z., LiX.K., ShengZ.Y.Morphological and distribution characteristics of sweat glands in hypertrophic scar and their possible effects on sweat gland regeneration. Chin Med J (Engl), 118:186. 2005.
10.
RudinM., WeisslederR.Molecular imaging in drug discovery and development. Nat Rev Drug Discov, 2:123. 2003.
AokiI., TakahashiY., ChuangK.H., SilvaA.C., IgarashiT., TanakaC., ChildsR.W., KoretskyA.P.Cell labeling for magnetic resonance imaging with the T1 agent manganese chloride. NMR Biomed, 19:50. 2006.
13.
RogersW.J., MeyerC.H., KramerC.M.Technology insight: in vivo cell tracking by use of MRI. Nat Clin Pract, 3:554. 2006.
14.
AdonaiN., NguyenK.N., WalshJ., IyerM., ToyokuniT., PhelpsM.E., McCarthyT., McCarthyD.W., GambhirS.S.Ex vivo cell labeling with 64Cu-pyruvaldehyde-bis(N4-methylthiosemicarbazone) for imaging cell trafficking in mice with positron-emission tomography. Proc Natl Acad Sci U S A, 99:3030. 2002.
15.
TjuvajevJ.G., DoubrovinM., AkhurstT., CaiS., BalatoniJ., AlauddinM.M., FinnR., BornmannW., ThalerH., ContiP.S.et al.Comparison of radiolabeled nucleoside probes (FIAU, FHBG, and FHPG) for PET imaging of HSV1-tk gene expression. J Nucl Med, 43:1072. 2002.
16.
BenninkR.J., van MontfransC., de JongeW.J., de BruinK., van DeventerS.J., te VeldeA.A.Imaging of intestinal lymphocyte homing by means of pinhole SPECT in a TNBS colitis mouse model. Nucl Med Biol, 31:93. 2004.
17.
BrennerW., AicherA., EckeyT., MassoudiS., ZuhayraM., KoehlU., HeeschenC., KampenW.U., ZeiherA.M., DimmelerS.et al.111In-labeled CD34+ hematopoietic progenitor cells in a rat myocardial infarction model. J Nucl Med, 45:512. 2004.
18.
KimY.H., LeeD.S., KangJ.H., LeeY.J., ChungJ.K., RohJ.K., KimS.U., LeeM.C.Reversing the silencing of reporter sodium/iodide symporter transgene for stem cell tracking. J Nucl Med, 46:305. 2005.
19.
SatoA., KlaunbergB., TolwaniR.In vivo bioluminescence imaging. Comp Med, 54:631. 2004.
20.
JosserandV., Texier-NoguesI., HuberP., FavrotM.C., CollJ.L.Non-invasive in vivo optical imaging of the lacZ and luc gene expression in mice. Gene Ther, 14:1587. 2007.
21.
ShahK., WeisslederR.Molecular optical imaging: applications leading to the development of present day therapeutics. NeuroRx, 2:215. 2005.
22.
HoshinoA., ManabeN., FujiokaK., SuzukiK., YasuharaM., YamamotoK.Use of fluorescent quantum dot bioconjugates for cellular imaging of immune cells, cell organelle labeling, and nanomedicine: surface modification regulates biological function, including cytotoxicity. J Artif Organs, 10:149. 2007.
VillarazaA.J., BumbA., BrechbielM.W.Macromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: the interplay between size, function, and pharmacokinetics. Chem Rev, 110:2921. 2010.
ViolaR.J., ProvenzaleJ.M., LiF., LiC.Y., YuanH., TashjianJ., DewhirstM.W.In vivo bioluminescence imaging monitoring of hypoxia-inducible factor 1alpha, a promoter that protects cells, in response to chemotherapy. AJR Am J Roentgenol, 191:1779. 2008.
30.
KuchimaruT., KadonosonoT., TanakaS., UshikiT., HiraokaM., Kizaka-KondohS.In vivo imaging of HIF-active tumors by an oxygen-dependent degradation protein probe with an interchangeable labeling system. PLoS One, 5:e15736. 2010.
31.
ChoeY.S., LeeK.H.Targeted in vivo imaging of angiogenesis: present status and perspectives. Curr Pharm Des, 13:17. 2007.
SchererR.L., McIntyreJ.O., MatrisianL.M.Imaging matrix metalloproteinases in cancer. Cancer Metastasis Rev, 27:679. 2008.
36.
BeerA.J., SchwaigerM.Imaging of integrin alphavbeta3 expression. Cancer Metastasis Rev, 27:631. 2008.
37.
ZaccaroL., Del GattoA., PedoneC., SavianoM.Peptides for tumour therapy and diagnosis: current status and future directions. Curr Med Chem, 16:780. 2009.
38.
MadedduP.Therapeutic angiogenesis and vasculogenesis for tissue regeneration. Exp Physiol, 90:315. 2005.
Leong-PoiH., ChristiansenJ., HeppnerP., LewisC.W., KlibanovA.L., KaulS., LindnerJ.R.Assessment of endogenous and therapeutic arteriogenesis by contrast ultrasound molecular imaging of integrin expression. Circulation, 111:3248. 2005.
41.
HuaJ., DobruckiL.W., SadeghiM.M., ZhangJ., BourkeB.N., CavaliereP., SongJ., ChowC., JahanshadN., van RoyenN.et al.Noninvasive imaging of angiogenesis with a 99mTc-labeled peptide targeted at alphavbeta3 integrin after murine hindlimb ischemia. Circulation, 111:3255. 2005.
42.
WinterP.M., CaruthersS.D., AllenJ.S., CaiK., WilliamsT.A., LanzaG.M., WicklineS.A.Molecular imaging of angiogenic therapy in peripheral vascular disease with alphanubeta3-integrin-targeted nanoparticles. Magn Reson Med, 64:369. 2010.
43.
RuppP.A., LittleC.D.Integrins in vascular development. Circ Res, 89:566. 2001.
44.
HiguchiT., WesterH.J., SchwaigerM.Imaging of angiogenesis in cardiology. Eur J Nucl Med Mol Imaging, 34,Suppl 1:S9. 2007.
45.
HartS.L., KnightA.M., HarbottleR.P., MistryA., HungerH.D., CutlerD.F., WilliamsonR., CoutelleC.Cell binding and internalization by filamentous phage displaying a cyclic Arg-Gly-Asp-containing peptide. J Biol Chem, 269:12468. 1994.
HabeebA.F.Determination of free amino groups in proteins by trinitrobenzenesulfonic acid. Anal Biochem, 14:328. 1966.
48.
BelderA.N.D., GranathK.Preparation and Properties of Fluorescein-Labeled Dextrans. Carbohyd Res, 30:375. 1973.
49.
KlotzU., KroemerH.Clinical pharmacokinetic considerations in the use of plasma expanders. Clin Pharmacokinet, 12:123. 1987.
50.
AlvaA., SlovinS., DaignaultS., CarducciM., DipaolaR., PientaK., AgusD., CooneyK., ChenA., SmithD.C.et al.Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. Invest New Drugs, 30:749. 2012.
51.
YamaokaT., TabataY., IkadaY.Body distribution profile of polysaccharides after intravenous adrninistration. Drug Deliv, 1:75. 1993.
52.
DuncanR.The dawning era of polymer therapeutics. Nat Rev Drug Discov, 2:347. 2003.
53.
DijkgraafI., RijndersA.Y., SoedeA., DechesneA.C., van EsseG.W., BrouwerA.J., CorstensF.H., BoermanO.C., RijkersD.T., LiskampR.M.Synthesis of DOTA-conjugated multivalent cyclic-RGD peptide dendrimers via 1,3-dipolar cycloaddition and their biological evaluation: implications for tumor targeting and tumor imaging purposes. Org Biomol Chem, 5:935. 2007.
54.
LiuS.Radiolabeled cyclic RGD peptides as integrin alpha(v)beta(3)-targeted radiotracers: maximizing binding affinity via bivalency. Bioconjug Chem, 20:2199. 2009.
55.
MontetX., FunovicsM., Montet-AbouK., WeisslederR., JosephsonL.Multivalent effects of RGD peptides obtained by nanoparticle display. J Med Chem, 49:6087. 2006.
56.
KeT., JeongE.K., WangX., FengY., ParkerD.L., LuZ.R.RGD targeted poly(L-glutamic acid)-cystamine-(Gd-DO3A) conjugate for detecting angiogenesis biomarker alpha(v) beta3 integrin with MRT, mapping. Int J Nanomed, 2:191. 2007.
57.
LesniakW.G., KariapperM.S., NairB.M., TanW., HutsonA., BaloghL.P., KhanM.K.Synthesis and characterization of PAMAM dendrimer-based multifunctional nanodevices for targeting alphavbeta3 integrins. Bioconjug Chem, 18:1148. 2007.
58.
TerrenoE., CastelliD.D., VialeA., AimeS.Challenges for molecular magnetic resonance imaging. Chem Rev, 110:3019. 2010.
59.
MassoudT.F., GambhirS.S.Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev, 17:545. 2003.
60.
ChtourouK., MaloulM., KallelF., CharfedineS., HamzaF., GuermaziF.SPECT and MRI fusion for an extended bilateral osteonecrosis. Eur J Nucl Med Mol Imaging, 35:2343. 2008.
61.
NtziachristosV., YodhA.G., SchnallM., ChanceB.Concurrent MRI and diffuse optical tomography of breast after indocyanine green enhancement. Proc Natl Acad Sci U S A, 97:2767. 2000.
VeisehO., SunC., GunnJ., KohlerN., GabikianP., LeeD., BhattaraiN., EllenbogenR., SzeR., HallahanA.et al.Optical and MRI multifunctional nanoprobe for targeting gliomas. Nano Lett, 5:1003. 2005.
64.
AraiY., FujitaM., MaruiA., HiroseK., SakaguchiH., IkedaT., TabataY., KomedaM.Combined treatment with sustained-release basic fibroblast growth factor and heparin enhances neovascularization in hypercholesterolemic mouse hindlimb ischemia. Circ J, 71:412. 2007.
65.
PatelZ.S., UedaH., YamamotoM., TabataY., MikosA.G.In vitro and in vivo release of vascular endothelial growth factor from gelatin microparticles and biodegradable composite scaffolds. Pharm Res, 25:2370. 2008.
66.
KimuraY., TabataY.Controlled release of stromal-cell-derived factor-1 from gelatin hydrogels enhances angiogenesis. J Biomater Sci Polym Ed, 21:37. 2010.
67.
CouffinhalT., SilverM., ZhengL.P., KearneyM., WitzenbichlerB., IsnerJ.M.Mouse model of angiogenesis. Am J Pathol, 152:1667. 1998.
68.
AlmutairiA., RossinR., ShokeenM., HagoolyA., AnanthA., CapocciaB., GuillaudeuS., AbendscheinD., AndersonC.J., WelchM.J.et al.Biodegradable dendritic positron-emitting nanoprobes for the noninvasive imaging of angiogenesis. Proc Natl Acad Sci U S A, 106:685. 2009.
